
Opinion|Videos|January 24, 2025
Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg
Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Aflibercept 8 mg was evaluated in the PULSAR and PHOTON trials for neovascular age-related macular degeneration and diabetic macular edema. Could you briefly review the design of these trials?
Newsletter
Advertisement






































